Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Blood (2024) 144 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2024-198499

Published: 2024

Journal Articles

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Blood (2024) 144 (Supplement 1): 7126.

https://doi.org/10.1182/blood-2024-194895

Published: 2024

Journal Articles

Outcomes of Salvage Radiotherapy in Relapsed/Refractory Large B-Cell Lymphoma Patients Following CAR T-Cell Therapy Failure: A Multicenter Pooled Analysis

Hazim Ababneh, Andrea Ng, Andrzej Niemierko, Matthew Frigault, Caron A. Jacobson, Chirayu Patel

Blood (2024) 144 (Supplement 1): 5112.

https://doi.org/10.1182/blood-2024-202163

Published: 2024

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Sairah Ahmed, Avyakta Kallam, Matthew Frigault, Bradley D. Hunter, Sagar S. Patel, David Bernasconi, Soyoung Kim, Tracy Krimmel, Fei Fei Liu, Debasmita Roy, Marcelo C. Pasquini, Jennifer L. Crombie

Blood (2024) 144 (Supplement 1): 472.

https://doi.org/10.1182/blood-2024-199702

Published: 2024

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood (2024) 144 (Supplement 1): 470.

https://doi.org/10.1182/blood-2024-199723

Published: 2024

Journal Articles

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Michael R Bishop, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika Banerjee, Rebecca J Chan, Ana Kostic, Christopher R. Heery, Tim Welliver, David Avigan, Andrzej J Jakubowiak, Matthew Frigault

Blood (2024) 144 (Supplement 1): 4825.

https://doi.org/10.1182/blood-2024-201080

Published: 2024

Journal Articles

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Magdi Elsallab, Moataz Ellithi, Matthew A. Lunning, Christopher D’Angelo, Jihyun Ma, Miguel-Angel Perales, Matthew Frigault, Marcela V. Maus

Blood (2024) 143 (20): 2099–2105.

https://doi.org/10.1182/blood.2024024166

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Matthew Frigault, Michael Heim, Stephen Ronan Foley, Brian T. Hill, Christine M. Ho, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Marta Majdan, Aisha Masood, Marcelo C Pasquini, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 1584–1587.

https://doi.org/10.1182/blood-2022-158822

Published: 2022

Journal Articles

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

Blood (2022) 140 (Supplement 1): 1056–1059.

https://doi.org/10.1182/blood-2022-162520

Published: 2022

Journal Articles

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Matthew Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Christine Cornwell, Kamalika Banerjee, Anand Rotte, Christopher R. Heery, David Avigan, Andrzej Jakubowiak, Michael R. Bishop

Blood (2022) 140 (Supplement 1): 7439–7440.

https://doi.org/10.1182/blood-2022-163827

Published: 2022

Journal Articles

Longitudinal Patient-Reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Patrick Connor Johnson, Tejaswini Dhawale, Mitchell W. Lavoie, Kyle Karpinski, Netana H. Markovitz, Kathleen Hennessey, Matthew Frigault, Areej El-Jawahri

Blood (2022) 140 (Supplement 1): 5232–5233.

https://doi.org/10.1182/blood-2022-163194

Published: 2022

Journal Articles

Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Tejaswini Dhawale, P. Connor Johnson, Mahmoud R. Gaballa, Ashley Nelson, Mitchell W. Lavoie, Matthew Frigault, Kofi Boateng, Claire Greydanus, Areej El-Jawahri

Blood (2022) 140 (Supplement 1): 10989–10990.

https://doi.org/10.1182/blood-2022-162494

Published: 2022

Journal Articles

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Michael Pratta, Lea Burke, John F. DiPersio, Richard T. Maziarz, Patricia Feldman, Teresa Brodeur, Cynthia Timmers, Olga Ivanova, April Barbour, Rodica Morariu-Zamfir, Matthew Frigault

Blood (2022) 140 (Supplement 1): 10350–10351.

https://doi.org/10.1182/blood-2022-169382

Published: 2022

Journal Articles

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Matthew Frigault, MD MSc, Megan Cartwright, PhD, Krista Marcello, BA, Timothy A Quill, PhD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Shilpa Paul, PharmD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 2199.

https://doi.org/10.1182/blood-2019-131533

Published: 2019

Journal Articles

Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells

Irene Scarfò, PhD, Kathleen Gallagher, Marcela V. Maus, MD PhD, Rebecca Larson, BS, Maegan Sheehan, BS, Gabrielle Brini, MSc, Scott Bornheimer, Mary Beth Hanley, Matthew Frigault, MD MSc, Mark Leick, MD, Alena Chekmasova, PhD

Blood (2019) 134 (Supplement_1): 5626.

https://doi.org/10.1182/blood-2019-128745

Published: 2019

NARROW

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Outcomes of Salvage Radiotherapy in Relapsed/Refractory Large B-Cell Lymphoma Patients Following CAR T-Cell Therapy Failure: A Multicenter Pooled Analysis

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Longitudinal Patient-Reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only